个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zheng X[1] * ; He X[2] * ; Yang Y[1] * ; Liu X[1] * ; Zhang L L[3] ; Qu B L[4] ; Zhong Q Z[5] ; Qian L T[6] ; Hou X R[7] ; Qiao X Y[8] ; Wang H[9] ; Zhu Y[10] ; Cao J Z[11] ; Wu J X[12] ; Wu T[13] ; Zhu S Y[14] ; Shi M[15] ; Xu L M[16] ; Zhang H L[16] ; Su H[17] ; Song Y Q[18] ; Zhu J[18] ; Zhang Y J[19] ; Huang H Q[19] ; Wang Y[20] ; Chen F[21] ; Yin L[21] ; Qi S N[1,*1] ; Li Y X[1,*1] ;
机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. [2]Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, PR China. [3]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China. [4]The General Hospital of Chinese People's Liberation Army, Beijing, PR China. [5]Beijing Hospital, National Geriatric Medical Center, Beijing, PR China. [6]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, PR China. [7]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, PR China. [8]The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China. [9]Second Affiliated Hospital of Nanchang University, Nanchang, PR China. [10]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Zhejiang, PR China. [11]Shanxi Cancer Hospital, the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China. [12]Fujian Provincial Cancer Hospital, Fuzhou, Fujian, PR China. [13]Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, PR China. [14]Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, PR China. [15]Xijing Hospital of Fourth Military Medical University, Xi'an, PR China. [16]Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, PR China. [17]The Fifth Medical Center of PLA General Hospital, Beijing, PR China. [18]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, PR China. [19]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, PR China. [20]Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing. [21]Affiliated Hospital of Qinghai University, Qinghai, PR China
出处：
DOI： 10.1016/j.esmoop.2021.100206
ISSN：

关键词： NK/T-cell lymphoma asparaginase chemotherapy radiotherapy survival outcome

摘要：
This study evaluated the survival benefit of asparaginase (ASP)-based versus non-ASP-based chemotherapy combined with radiotherapy in a real-world cohort of patients with early-stage extranodal nasal-type natural killer/T-cell lymphoma (ENKTCL).We identified 376 patients who received combined radiotherapy with either ASP-based (ASP, platinum, and gemcitabine; n = 286) or non-ASP-based (platinum and gemcitabine; n = 90) regimens. The patients were stratified into low-, intermediate-, and high-risk groups using the early stage-adjusted nomogram-revised risk index. Overall survival (OS) and distant metastasis (DM)-free survival (DMFS) between the chemotherapy regimens were compared using inverse probability of treatment weighting (IPTW) and multivariable analyses.ASP-based (versus non-ASP-based) regimens significantly improved 5-year OS (84.5% versus 73.2%, P = 0.021) and DMFS (84.4% versus 74.5%, P = 0.014) for intermediate- and high-risk patients, but not for low-risk patients in the setting of radiotherapy. Moreover, ASP-based regimens decreased DM, with a 5-year cumulative DM rate of 14.9% for ASP-based regimens compared with 25.1% (P = 0.014) for non-ASP-based regimens. The survival benefit of ASP-based chemotherapy and radiotherapy remained consistent after adjusting the confounding variables using IPTW and multivariate analyses; additional sensitivity analyses confirmed these results.The findings provided support for ASP-based chemotherapy and radiotherapy as a first-line treatment strategy for intermediate- and high-risk early-stage ENKTCL.Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

基金：
Chinese Academy of Medical Science (CAMS) Innovation Fund for Medical Sciences (CIFMS), [grant number 2016-I2M-1-001], the National Key Projects of Research and Development of China [grant number 2016YFC0904600], and National Natural Science Foundation of China [grant number 81670185].

基金编号： grant number 2016-I2M-1-001

语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
共同第一作者：
通讯作者：
通讯机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. [*1]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China [*2]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
推荐引用方式(GB/T 7714)：
Zheng X,He X,Yang Y,et al.Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.[J].ESMO OPEN.2021,6(4):doi:10.1016/j.esmoop.2021.100206.
APA：
Zheng X,He X,Yang Y,Liu X,Zhang L L...&Li Y X.(2021).Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study..ESMO OPEN,6,(4)
MLA：
Zheng X,et al."Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.".ESMO OPEN 6..4(2021)

相关文献

[1]Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma. [2]Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma [3]The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma [4]Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. [5]Treatment Benefit Associating with Non-Anthracycline Chemotherapy in Extranodal NK/T-Cell Lymphoma, Nasal Type: A Multicenter Study from the China Lymphoma Collaborative Group (CLCG) [6]First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. [7]PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity [8]Evidence of Cure for Extranodal Nasal-Type NK/T-Cell Lymphoma with Modern Treatment [9]Solitary Epstein-Barr virus-positive cytotoxic T cell lymphoproliferative disease in stomach mimicking extranodal NK/T cell lymphoma [10]Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

资源点击量：42313 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号